The progression of chimeric antigen receptor modified T cells in malignant tumor
10.3760/cma.j.issn.1673-422X.2014.07.005
- VernacularTitle:嵌合抗原受体修饰T细胞在恶性肿瘤中的研究进展
- Author:
Shaohua ZHANG
;
Jingwang BI
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Immunotherapy;
Chimericantigenreceptor
- From:
Journal of International Oncology
2014;(7):495-499
- CountryChina
- Language:Chinese
-
Abstract:
Recentyearshavewitnessedmuchprogressinbothbasicresearchandclinicaltrialsregar-ding cancer immunotherapy with chimeric antigen receptor (CAR)-engineered T cells.CAR combine the varia-ble regions of a specific monoclonal antibody (scFv)with the CD3ζendodomain.The extracellular domain of CAR-engineered T cells directly dock to the tumor-associated antigen (TAA).When T cells bind to target anti-gens,they mediated redirected cytotoxicity and secrete a series of cytokines such as Perforin,Granzyme,Inter-feron-γ(IFN-γ)and Tumor necrosis factor-α(TNF-α),which would eventually lead to the necrosis of tumor cells.Although the antitumor response of the CAR-engineered T cells is considered as successful and surpri-sing,it should be noted that some safety issues have been observed in other several basic researches and clinical trials.This overview focuses upon the utility and safety of the CAR-engineered T cells.
